Femasys Inc (FEMY) stock
Close on Nov 11, 2026Market cap $12.56MP/E –Yield –
Femasys Inc grew revenue 21.9% to $2.30M over the twelve months to Jun 30, 2026. Free cash flow was -$18.07M. At the latest close the market valued the company at $12.56M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.56M
- P/E ratio
- –
- Price to sales
- 5.46
- Price to book
- 3.12
- Dividend yield
- –
- Free cash flow yield
- -143.88%
Fundamentals
- Revenue
- $2.30M
- Net income
- -$11.77M
- EPS, diluted
- -$4.58
- Free cash flow
- -$18.07M
- Book value per share
- $1.20
- Diluted shares
- 3M
Trading
- Next earnings
- Nov 13, 2026 (estimated, after the close)
- Previous close
- $1.43
- Open
- $1.44
- Day's range
- $1.42 – $1.53
- Volume
- 82,509
- Average volume (20 days)
- 103,755
- Beta (5 years)
- 0.44
- 52-week range
- $1.25 – $22.20
- RSI (14 days)
- 42.8
- Volatility (1 year)
- 101.2%
- Relative volume
- 0.15×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FEMY | S&P 500 | Difference | FEMY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.0% | -2.4% | −22.6 pts | ||
| 3 months | -36.2% | -1.2% | −35.0 pts | ||
| Year to date | -87.0% | +12.3% | −99.3 pts | ||
| 1 year | -92.0% | +12.4% | −104.5 pts | ||
| 3 years | -93.9% | +78.8% | −172.7 pts | -60.5% | +21.4% |
| 5 years | -99.0% | +75.2% | −174.2 pts | -60.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Femasys filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- News
- Update
- Results
- News
About Femasys
Surgical & Medical Instruments & Apparatus
Femasys Inc. is a biomedical company specializing in women’s healthcare solutions. The company develops and commercializes in-office therapeutic and diagnostic products designed to address unmet needs in reproductive health, permanent contraception, and cancer screening. Its product offerings include FemaSeed, an intratubal insemination treatment for infertility; FemVue, FemVue Controlled, and FemChec, which are diagnostic ultrasound contrast systems for evaluating fallopian tube patency; FemSperm kits for semen preparation and analysis; and FemCerv, a tissue sampler for cervical cancer diagnosis. Femasys is also developing FemBloc, a non-surgical permanent birth control system. Its operations primarily serve healthcare providers, such as gynecologists, reproductive endocrinologists, and infertility centers, as well as their patients.
Company profile, executives and historyFemasys stock: common questions
What is Femasys's stock price?
FEMY closed at $1.50 on Nov 11, 2026, up 4.90% on the day. Over the past 52 weeks it traded between $1.25 and $22.20.
What is Femasys's market cap?
Femasys was worth $12.56M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FEMY's P/E ratio?
Femasys lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.58), so it has no meaningful P/E ratio.
How much revenue does Femasys make?
Femasys reported revenue of $2.30M for the twelve months to Jun 30, 2026, up 21.9% from a year earlier.
Does Femasys pay a dividend?
No. Femasys has not paid a cash dividend over the last twelve months.
When does Femasys report earnings next?
Femasys is expected to report Q3 FY2026 results on Nov 13, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has FEMY stock performed over the past year?
Including dividends, FEMY returned -92.0% over the past year, against +12.4% for the S&P 500.
How many FEMY shares are sold short?
0M shares were sold short at the latest FINRA report, 4.19% of the float, or 1.0 days of average trading volume.
Who are Femasys's competitors?
Companies most similar to Femasys by business, industry and size include IVF, OSRH, INBS, ICCM, SINT.
See a number that looks wrong?